In an experimental autoimmune encephalomyelitis (EAE) model, blocking BCAT1-mediated leucine catabolism using BCAT1 inhibitors or LβhL treatment alleviated the severity of EAE by reducing HIF1α expression and IL-17 production in spinal cord mononuclear cells. Here, BCAT1 is linked to experimental autoimmune encephalomyelitis.